GlassScriptPhysician profile
Stanley J Shin
NPI 1801835194
$3,699.88
in general payments reported to CMS, 2019-2025
32 companies · $415 in 2025
The $415 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $208 · 2021: $673 · 2022: $975 · 2023: $666 · 2024: $228 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $466.02 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $372.10 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $300.53 | 2019-2023 | Xarelto |
| Pfizer INC. | $270.53 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $249.12 | 2019-2024 | |
| Atricure, INC. | $239.08 | 2019-2022 | |
| Edwards Lifesciences Corporation | $217.37 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $210.15 | 2019-2024 | Watchman Flx, Varithena Administration Pack, Lux-Dx Insertable Cardiac Monitor |
| Vital Connect, INC | $151.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $147.65 | 2022-2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.32 | 2019-2023 | Jardiance |
| Abbott Laboratories | $122.39 | 2020-2025 | Mitraclip |
| Amarin Pharma, INC. | $93.09 | 2019-2022 | |
| Philips North America LLC | $85.21 | 2020-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bard Peripheral Vascular, INC. | $83.62 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $73.38 | 2021 | |
| Ironshore Pharmaceuticals INC. | $71.11 | 2022 | |
| Abiomed | $60.25 | 2024-2025 | Impella |
| Amgen INC. | $42.77 | 2019 | |
| Merck Sharp & Dohme LLC | $41.02 | 2021-2022 | |
| Cvrx, INC. | $39.49 | 2023-2024 | Barostim Neo System |
| Novo Nordisk INC | $32.77 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Stryker Corporation | $29.12 | 2025 | Flowtriever |
| Cashflow Solutions, LLC | $23.62 | 2023-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Astellas Pharma US INC | $22.11 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $21.37 | 2023 | Inpefa |
| Inari Medical, INC. | $19.56 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| United Therapeutics Corporation | $18.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.45 | 2025 | |
| Glaxosmithkline, LLC. | $14.65 | 2025 | Shingrix, Arexvy |
| Baxter Healthcare | $13.81 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.